Planning for Sustainability in Small Municipalities: The Influence of Interest Groups, Growth Patterns, and Institutional Characteristics

How and why small municipalities promote sustainability through planning efforts is poorly understood. We analyzed ordinances in 451 Maine municipalities and tested theories of policy adoption using regression analysis.We found that smaller communities do adopt programs that contribute to sustainability relevant to their scale and context. In line with the political market theory, we found that municipalities with strong environmental interests, higher growth, and more formal governments were more likely to adopt these policies. Consideration of context and capacity in planning for sustainability will help planners better identify and benefit from collaboration, training, and outreach opportunities

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment

Mathematical modelling of drug release from a porous granule

Understanding drug release from pharmaceutical granules is vital to the development of targeted release profiles. A model describing diffusion and solubility-limited drug dissolu tion and release from a porous spherical granule of drug and excipient is considered. Ra dially varying porosity and initial concentration profiles which can arise in pharmaceutical granules are incorporated. A range of boundary-value and moving-boundary-value prob lems arise, depending on the relationship between the drug saturation concentration in the solvent medium and the initial drug concentration and porosity profiles. The model is derived in detail for the case where the initial drug concentration is greater than the drug saturation concentration in all parts of the granule. In this case, a moving bound ary forms at the granule surface and propagates inwards, separating an unextracted in ner core from a shell region which undergoes extraction via diffusion. The full model is non-dimensionalised and analysed using asymptotic methods and numerical solution. A leading-order model is derived by exploiting a small parameter corresponding to the ratio of the drug saturation concentration to the maximum initial concentration in the gran ule, allowing estimation of the time taken for the moving boundary to reach the granule centre. The behaviour of the full model is considered by solving it using a boundary immo bilisation method and the finite element method for a range of parameters and comparing to the leading-order model. Finally, the model outputs for the moving boundary position and normalised drug release are compared with experimental data from the literature

Identification of Two Genes, sll0804 and slr1306, as Putative Components of the CO2-Concentrating Mechanism in the Cyanobacterium Synechocystis sp. Strain PCC 6803 ▿

Insertional transposon mutations in the sll0804 and slr1306 genes were found to lead to a loss of optimal photoautotrophy in the cyanobacterium Synechocystis sp. strain PCC 6803 grown under ambient CO2 concentrations (350 ppm). Mutants containing these insertions (4BA2 and 3ZA12, respectively) could grow photoheterotrophically on glucose or photoautotrophically at elevated CO2 concentrations (50,000 ppm). Both of these mutants exhibited an impaired affinity for inorganic carbon. Consequently, the Sll0804 and Slr1306 proteins appear to be putative components of the carbon-concentrating mechanism in Synechocystis sp. strain PCC 6803

A moving-boundary model of dissolution from binary drug-excipient granules incorporating microstructure.

Accurate mechanistic in vitro dissolution models can deliver insight into drug release behaviour and guide formulation development. Drug release profiles from drug-excipient granules can be impacted by variation of porosity and drug load within granules, which may arise from inherent variability in granulation processes. Here, we analyse and validate a recent model of drug release from a single spherical granule with a matrix of insoluble excipient, incorporating radial variation of porosity and drug load. The model is presented and specialised to the case where the initial drug load is large compared to the capacity of the granule's pores at solubility. In this limit, the model reduces to a single ordinary differential equation describing depletion of a shrinking, drug-saturated core. Model validation is performed using drug release data from the literature for a granule system consisting of acetaminophen and microcrystalline cellulose. A new extended model to describe dissolution from a polydisperse collection of granules is derived. The performance is compared to single particle models using equivalent spherical diameters. The developed model provides a new tool to explore the dissolution parameter space for these systems and for considering the impact of radial variation of granule porosity and drug load arising from manufacturing processes

Asymptotic analysis of the dominant mechanisms in the coffee extraction process

Extraction of coffee solubles from roast and ground coffee is a highly complex process, depending on a large number of brewing parameters. We consider a recent, experimentally validated, model of coffee extraction, describing extraction from a coffee bed using a double porosity model, which includes dissolution and transport of coffee. It was shown that this model can accurately describe coffee extraction in two situations: extraction from a dilute suspension of coffee grains and extraction from a packed coffee bed. Despite being based on some simplifying assumptions, this model can only be solved numerically. In this paper we consider asymptotic solutions of the model describing extraction from a packed coffee bed. Such solutions can explicitly relate coffee concentration to the process parameters. For an individual coffee grain, extraction is controlled by a rapid dissolution of coffee from the surface of the grain, in conjunction with a slower diffusion of coffee through the intragranular pore network to the grain surface. Extraction of coffee from the bed also depends on the speed of advection of coffee from the bed. We utilize the small parameter resulting from the ratio of the advection timescale to the grain diffusion timescale to construct asymptotic solutions using the method of matched asymptotic expansions. The asymptotic solutions are compared to numerical solutions and data from coffee extraction experiments. The asymptotic solutions depend on a small number of dimensionless parameters and so are useful to quickly fit extraction curves and investigate the influence of various process parameters on the extraction